Proton pump inhibitor – CRI Report https://www.cri-report.com market research vender! Thu, 02 Dec 2021 07:18:45 +0000 en-US hourly 1 https://www.cri-report.com/wp-content/uploads/2021/01/cropped-shcrilogo-c.jpg Proton pump inhibitor – CRI Report https://www.cri-report.com 32 32 Investigation Report on China’s Rabeprazole Market 2021-2025 https://www.cri-report.com/investigation-report-on-chinas-rabeprazole-market-2021-2025/ Fri, 04 Jun 2021 06:22:12 +0000 https://www.cri-report.com/?post_type=product&p=11709 According to CRI's market research, the sales value of Rabeprazole in the Chinese market increased year by year from 2016 to 2019.

The post Investigation Report on China’s Rabeprazole Market 2021-2025 first appeared on CRI Report.

]]> Rabeprazole is a kind of proton pump inhibitor (PPI) gastric acid inhibitor. It is used for the treatment of gastroesophageal reflux disease and maintenance treatment after recovery. It is also suitable for the treatment of duodenal ulcers and Zollinger-Ellison syndrome. Rabeprazole’s product PARIET, developed by Eisai Pharmaceutical Co., Ltd. of Japan, was approved in China in 2000. As of the end of 2020, there are more than 10 manufacturers in the Chinese Rabeprazole market, of which Jiangsu Aosaikang Pharmaceutical Co., Ltd. accounts for the largest market share.

According to CRI’s market research, the sales value of Rabeprazole in the Chinese market increased year by year from 2016 to 2019. Due to the impact of the COVID-19 epidemic on the overall medical diagnosis and treatment services, the sales value decreased to CNY1.334 billion in 2020, with a year-on-year decrease of 11.01%. The CAGR of the sales value of Rabeprazole from 2016 to 2020 is 9.66% in China.

CRI predicts that the sales of Rabeprazole will have a restorative growth from 2021 to 2025 with the effective alleviation of the Covid-19 epidemic. At the same time, only Rabeprazole injections among the six PPI injections listed in China are not listed in the national medical insurance catalog as of the first half of 2021. It may enter medical insurance in the future, prompting sales to continue to increase. In addition, Rabeprazole has no obvious individual differences. Rabeprazole has stabler efficacy and has less interaction with other drugs compared with similar drugs,. Based on these advantages, it is expected that the sales of Rabeprazole in the Chinese market will continue to rise from 2021 to 2025.

Topics Covered:
-The impact of COVID-19 on China’s Rabeprazole market
– Sales value of China’s Rabeprazole 2016-2020
– Competitive landscape of China’s Rabeprazole market
– Prices of Rabeprazole in China
– Prices of Rabeprazole in China by regions and manufacturers
– Analysis of factors affecting the development of China’s Rabeprazole market
– Prospect of China’s Rabeprazole market from 2021 to 2025

The post Investigation Report on China’s Rabeprazole Market 2021-2025 first appeared on CRI Report.

]]> Investigation Report on China’s Pantoprazole Market 2021-2025 https://www.cri-report.com/investigation-report-on-chinas-pantoprazole-market-2021-2025/ Fri, 04 Jun 2021 06:22:52 +0000 https://www.cri-report.com/?post_type=product&p=11718 The sales value of pantoprazole in the Chinese market has shown an overall upward trend from 2016 to 2020, with a CAGR of 3.06% from 2016 to 2020.

The post Investigation Report on China’s Pantoprazole Market 2021-2025 first appeared on CRI Report.

]]> Pantoprazole is the third proton pump inhibitor marketed globally. Compared with omeprazole, it has higher selectivity and bioavailability. Pantoprazole is more stable than omeprazole and lansola under weak acid conditions. The product of Pantoprazole, developed by Byk Gulden of Germany, can treat duodenal ulcer; gastric ulcer; moderate and severe reflux esophagitis. It was approved for listing in China in 1999. By the end of 2020, there are several manufacturers in the Chinese Pantoprazole market.

According to CRI’s market research, the sales value of pantoprazole in the Chinese market has declined continuously from 2016 to 2020, and its sales value reached CNY 1.162 billion in 2020. The sales value of pantoprazole in the Chinese market has shown an overall upward trend from 2016 to 2020, with a CAGR of 3.06% from 2016 to 2020.

CRI expects that with the effective alleviation of the COVID-19 epidemic, the sales of pantoprazole will have a restorative growth from 2016 to 2020. Pantoprazole has the advantages of stable curative effect, good acid suppression effect, and small short-term side effects. Therefore, the sales of pantoprazole in China will maintain a growth trend in the future.

Topics Covered:
-The impact of COVID-19 on China’s Pantoprazole market
– Sales value of China’s Pantoprazole 2016-2020
– Competitive landscape of China’s Pantoprazole market
– Prices of Pantoprazole in China
– Prices of Pantoprazole in China by regions and manufacturers
– Analysis of factors affecting the development of China’s Pantoprazole market
– Prospect of China’s Pantoprazole market from 2021 to 2025

The post Investigation Report on China’s Pantoprazole Market 2021-2025 first appeared on CRI Report.

]]> Investigation Report on China’s Esomeprazole Market 2021-2025 https://www.cri-report.com/investigation-report-on-chinas-esomeprazole-market-2021-2025/ Thu, 27 May 2021 06:56:10 +0000 https://www.cri-report.com/?post_type=product&p=11654 According to CRI analysis, the sales of Esomeprazole have grown steadily from 2016 to 2019. In 2020, its sales fell by about 6% to CNY1.561 billion in 2020.

The post Investigation Report on China’s Esomeprazole Market 2021-2025 first appeared on CRI Report.

]]> Description
Esomeprazole is a proton pump inhibitor (PPI), which can effectively inhibit gastric acid secretion. It is clinically used to treat gastric acid-related diseases such as gastroesophageal reflux disease (GERD) and erosive reflux esophagitis (ERD). Its product, NEXIUM was developed by AstraZeneca AB. Esomeprazole was approved in China in 2007. By 2020, in addition to AstraZeneca AB, there are more than 10 generic drug manufacturers in the Chinese Esomeprazole market, such as Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Jiangsu Aosaikang Pharmaceutical Co., Ltd. and Chongqing Lummy Pharmaceutical Co., Ltd.

According to CRI analysis, the sales of Esomeprazole have grown steadily from 2016 to 2019. In 2020, its sales fell by about 6% to CNY1.561 billion in 2020. The main reason is that the Covid-19 epidemic has affected the hospital’s overall diagnosis and treatment business, resulting in a decline in its sales. The CAGR of Esomeprazole sales in the Chinese market from 2016 to 2020 is 12%.

CRI predicts that the sales volume of Esomeprazole in the Chinese market will have a restorative growth from 2021 to 2025 with the effective alleviation of the Covid-19 epidemic. In addition, as of the first half of 2021, there are 13 pharmaceutical companies that have applied to enter the Esomeprazole market in China. It can be expected that the price of Esomeprazole will decrease with the addition of new manufacturers, and both sales and sales volume will grow. Moreover, compared with similar drugs, Esomeprazole has the advantages of short-course therapy, stable curative effect, fast and long-lasting effect, so the sales volume of Esomeprazole in China will maintain a growth trend.

Topics Covered:
-The impact of COVID-19 on China’s Esomeprazole market
– Sales value of China’s Esomeprazole 2016-2020
– Competitive landscape of China’s Esomeprazole market
– Prices of Esomeprazole in China
– Prices of Esomeprazole in China by regions and manufacturers
– Analysis of factors affecting the development of China’s Esomeprazole market
– Prospect of China’s Esomeprazole market from 2021 to 2025

The post Investigation Report on China’s Esomeprazole Market 2021-2025 first appeared on CRI Report.

]]>